기본 통계
| CIK | 1531177 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Sight Sciences, Inc.
SEC Filings (Chronological Order)
이 페이지는 다른 곳에서 제공하는 소유권 보고서를 제외한 SEC 보고서의 전체 리스트를 시간 순으로 정리한 것입니다.
| May 29, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report SIGHT SCIENCES, INC. (Exact name of the registrant as specified in its charter) Delaware 001-40587 80-0625749 (State or other jurisdiction of (Commission (IRS Employer incorporation or organization) File Number) Identification No.) 4040 Campbell Ave, Suite 100 Menlo Park, CA 94025 (Address |
|
| May 29, 2026 |
Exhibit 1.01 CONFLICT MINERALS REPORT OF SIGHT SCIENCES, INC. FOR THE REPORTING PERIOD FROM JANUARY 1 TO DECEMBER 31, 2025 I. Introduction This is the Conflict Minerals Report1 of Sight Sciences, Inc. (“we,” “our,” “us,” “Sight Sciences,” or the “Company”) prepared for calendar year 2025 in accordance with Rule 13p-1 (“Rule 13p-1”) under the Securities Exchange Act of 1934 (the “Act”). Numerous te |
|
| May 6, 2026 |
FORM 8-K Item 2.02 Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 06, 2026 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 6, 2026 |
Exhibit 99.1 Sight Sciences Reports First Quarter 2026 Financial Results and Raises Full Year 2026 Revenue Guidance MENLO PARK, Calif., May 6, 2026 (GLOBE NEWSWIRE) - Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ |
|
| May 6, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40587 SIGHT SCIENCES, INC. |
|
| May 6, 2026 |
Investor Presentation May 2026 Investor Presentation May 2026 Forward-Looking Statements This presentation, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which statements are subject to considerable risks and uncertainties. |
|
| April 23, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2026 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| April 22, 2026 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 22, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 30, 2026 |
Exhibit 99.1 Sight Sciences Secures Order on Post-Trial Motions That Preserves the Jury’s Verdict and Awards Monetary Damages to Sight Sciences Against Alcon and its Hydrus® Microstent Court preserves jury’s finding of willful infringement by Alcon, and awards past damages to Sight Sciences in excess of $34 million and ongoing royalties through November 2028 MENLO PARK, Calif. – March 30, 2026 - ( |
|
| March 30, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2026 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| March 4, 2026 |
Exhibit 10.20 SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”), dated as of June 17, 2025, is entered into by and among SIGHT SCIENCES, INC., a Delaware corporation (“Company”), and each other Person that has delivered a Joinder Agreement pursuant to Section 7.13 party hereto (together with Company, individually or collectively, as |
|
| March 4, 2026 |
Investor Presentation March 2026 Investor Presentation March 2026 Forward-Looking Statements This presentation, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which statements are subject to considerable risks and uncertainties. |
|
| March 4, 2026 |
Sight Sciences,, Inc. Insider Trading Compliance Policy Exhibit 19.1 Sight Sciences,, Inc. Insider Trading Compliance Policy This Insider Trading Compliance Policy (this “Policy”) consists of seven sections: • Section I provides an overview; • Section II sets forth the policies of the Company prohibiting insider trading; • Section III explains insider trading; • Section IV consists of procedures that have been put in place by the Company to prevent ins |
|
| March 4, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40587 SIGHT SCIENCES, |
|
| March 4, 2026 |
SECOND AMENDMENT TO MULTI-TENANT SPACE LEASE RECITALS AGREEMENT LANDLORD: TENANT: Exhibit 10.15 SECOND AMENDMENT TO MULTI-TENANT SPACE LEASE This Second Amendment To Multi-Tenant Space Lease (this "Second Amendment"), dated as of January 29, 2026 (the “Reference Date”), is made and entered into by and between Deerfield Campbell LLC, a California limited liability company ("Landlord"), and Sight Sciences, Inc., a Delaware corporation ("Tenant"), with reference to those matters s |
|
| March 4, 2026 |
FORM 8-K Item 2.02 Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 04, 2026 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| March 4, 2026 |
Exhibit 10.12 Employment Agreement This Employment Agreement (this “Agreement”), effective as of November 5, 2025 (the “Effective Date”), is made by and between Sight Sciences, Inc., a Delaware corporation (together with any successor thereto, the “Company”), and James Rodberg (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”). RECITALS A. It |
|
| March 4, 2026 |
Exhibit 24.1 POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Paul Badawi and James Rodberg, and each of them individually, his and her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him and her and in his and her name, place, and stead, in any and all capaciti |
|
| March 4, 2026 |
Exhibit 99.1 Sight Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Initiates Full Year 2026 Financial Guidance MENLO PARK, Calif., March 4, 2026 (GLOBE NEWSWIRE) - Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care |
|
| March 4, 2026 |
Amended and Restated Employment Agreement Exhibit 10.10 Amended and Restated Employment Agreement This Amended and Restated Employment Agreement (this “Agreement”), effective as of November 5, 2025 (the “Effective Date”), is made by and between Sight Sciences, Inc., a Delaware corporation (together with any successor thereto, the “Company”), and Alison Bauerlein (“Executive”) (collectively referred to herein as the “Parties” or individual |
|
| February 3, 2026 |
FORM 8-K Item 1.01 Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2026 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| January 13, 2026 |
FORM 8-K Item 2.02 Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2026 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| January 13, 2026 |
Exhibit 99.1 Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Highlights MENLO PARK, Calif., January 13, 2026 (GLOBE NEWSWIRE) - Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients |
|
| November 6, 2025 |
Exhibit 99.2 Sight Sciences Appoints Ali Bauerlein as Chief Operating Officer and Jim Rodberg as Chief Financial Officer New leadership appointments strengthen Sight Sciences’ commitment to advancing our interventional dry eye initiatives and driving scalable operations and growth MENLO PARK, Calif., November 6, 2025 (GLOBE NEWSWIRE) - Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences, or the Co |
|
| November 6, 2025 |
FORM 8-K Item 2.02 Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 04, 2025 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 6, 2025 |
Sight Sciences Investor Presentation November 2025 Sight Sciences Investor Presentation November 2025 Forward-Looking Statements This presentation, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which statements are subject to considerable risks and uncertainties. |
|
| November 6, 2025 |
Exhibit 99.1 Sight Sciences Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance MENLO PARK, Calif., August 7, 2025 (GLOBE NEWSWIRE) - Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ |
|
| November 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40587 SIGHT SCIENCES, INC. |
|
| October 17, 2025 |
Creating a New Category for Reimbursed Interventional Dry Eye Treatment Investor Presentation October 2025 Forward-Looking Statements This presentation, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which statements are subject to considerable risks and uncertainties. |
|
| October 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2025 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| October 17, 2025 |
Exhibit 99.1 Sight Sciences Announces Fee Schedule Establishment from Novitas Solutions and First Coast Service Options for the TearCare® Interventional Dry Eye Procedure MENLO PARK, Calif., October 17, 2025— Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended t |
|
| October 6, 2025 |
144 0001596103 XXXXXXXX LIVE 0001531177 Sight Sciences, Inc. 001-40587 4040 CAMPBELL AVE, SUITE 100 MENLO PARK CA 94025 (415) 889-0550 Taylor Brenton Officer Common Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917 591 1992.32 52367359 10/06/2025 NASDAQ Common 09/30/2025 Restricted Stock Vesting Issuer N 591 09/30/2025 Compensation Y Sale includes an amount necessary to cover a |
|
| October 3, 2025 |
144 0001650737 XXXXXXXX LIVE 0001531177 Sight Sciences, Inc. 001-40587 4040 CAMPBELL AVE, SUITE 100 MENLO PARK CA 94025 (415) 889-0550 HAYDEN JEREMY B. Officer Common Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917 9731 31848.59 52367359 10/03/2025 NASDAQ Common 09/30/2025 Restricted Stock Vesting Issuer N 9731 09/30/2025 Compensation N Jeremy Hayden 4040 Campbell Ave, Suite 1 |
|
| October 3, 2025 |
144 0001565950 XXXXXXXX LIVE 0001531177 Sight Sciences, Inc. 001-40587 4040 CAMPBELL AVE, SUITE 100 MENLO PARK CA 94025 (415) 889-0550 Link Matthew Former Officer Common Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917 15000 49276.20 52367359 10/03/2025 NASDAQ Common 10/17/2024 Restricted Stock Vesting Issuer N 11236 10/17/2024 Compensation Common 10/18/2024 Restricted Stock Ve |
|
| October 3, 2025 |
144 0001870825 XXXXXXXX LIVE 0001531177 Sight Sciences, Inc. 001-40587 4040 CAMPBELL AVE, SUITE 100 MENLO PARK CA 94025 (415) 889-0550 Badawi David Officer Director Common Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917 6033 19745.41 52367359 10/03/2025 NASDAQ Common 09/30/2025 Restricted Stock Vesting Issuer N 6033 09/30/2025 Compensation N David Y. Badawi 4040 Campbell Ave S |
|
| October 2, 2025 |
144 0001596080 XXXXXXXX LIVE 0001531177 Sight Sciences, Inc. 001-40587 4040 CAMPBELL AVE, SUITE 100 MENLO PARK CA 94025 (415) 889-0550 Bauerlein Alison Officer Common Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917 19948 65750.60 52367359 10/02/2025 NASDAQ Common 09/30/2025 Restricted Stock Vesting Issuer N 19948 09/30/2025 Compensation N Alison Bauerlein 4040 Campbell Ave Sui |
|
| October 1, 2025 |
144 0001870865 XXXXXXXX LIVE 0001531177 Sight Sciences, Inc. 001-40587 4040 CAMPBELL AVE, SUITE 100 MENLO PARK CA 94025 (415) 889-0550 Badawi Paul Officer Director Common Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917 24441 81740.48 52367359 10/01/2025 NASDAQ Common 09/30/2025 Restricted Stock Vesting Issuer N 24441 09/30/2025 Compensation N Paul Badawi 4040 Campbell Ave Suit |
|
| September 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2025 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission |
|
| September 30, 2025 |
THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT Exhibit 10.1 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”), dated as of September 30, 2025, is |
|
| September 23, 2025 |
144 0001565950 XXXXXXXX LIVE 0001531177 Sight Sciences, Inc. 001-40587 4040 CAMPBELL AVE, SUITE 100 MENLO PARK CA 94025 (415) 889-0550 Link Matthew Former Officer Common Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917 20753 73350.73 52367359 09/23/2025 NASDAQ Common 10/16/2024 Restricted Stock Vesting Issuer N 5753 10/16/2024 Compensation Common 10/17/2024 Restricted Stock Ves |
|
| September 19, 2025 |
144 0001565950 XXXXXXXX LIVE 0001531177 Sight Sciences, Inc. 001-40587 4040 CAMPBELL AVE, SUITE 100 MENLO PARK CA 94025 (415) 889-0550 Link Matthew Former Officer Common Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917 20000 73400.00 52367359 09/19/2025 NASDAQ Common 10/16/2024 Restricted Stock Vesting Issuer N 20000 10/16/2024 Compensation N Matthew Link 4040 Campbell Ave, Sui |
|
| September 16, 2025 |
144 0001565950 XXXXXXXX LIVE 0001531177 Sight Sciences, Inc. 001-40587 4040 CAMPBELL AVE, SUITE 100 MENLO PARK CA 94025 (415) 889-0550 Link Matthew Former Officer Common Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917 15990 55291.81 52367359 09/16/2025 NASDAQ Common 10/15/2024 Restricted Stock Vesting Issuer N 15990 10/15/2024 Compensation N Matthew Link 4040 Campbell Ave Suit |
|
| September 12, 2025 |
144 0001565950 XXXXXXXX LIVE 0001531177 Sight Sciences, Inc. 001-40587 4040 CAMPBELL AVE, SUITE 100 MENLO PARK CA 94025 (415) 889-0550 Link Matthew Former Officer Common Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917 10000 35227.21 52367359 09/12/2025 NASDAQ Common 10/15/2024 Restricted Stock Vesting Issuer N 10000 10/15/2024 Compensation N Matthew Link 4040 Campbell Ave Suit |
|
| August 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 27, 2025 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40587 SIGHT SCIENCES, INC. |
|
| August 7, 2025 |
FORM 8-K Item 2.02 Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 07, 2025 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| August 7, 2025 |
Sight Sciences Investor Presentation August 2025 Sight Sciences Investor Presentation August 2025 Forward-Looking Statements This presentation, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which statements are subject to considerable risks and uncertainties. |
|
| August 7, 2025 |
Exhibit 99.1 Sight Sciences Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance MENLO PARK, Calif., August 7, 2025 (GLOBE NEWSWIRE) - Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ |
|
| June 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2025 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 30, 2025 |
Conflict Minerals Report as required by Item 1.01 and 1.02 of this Form SD. Exhibit 1.01 CONFLICT MINERALS REPORT OF SIGHT SCIENCES, INC. FOR THE REPORTING PERIOD FROM JANUARY 1 TO DECEMBER 31, 2024 I. Introduction This is the Conflict Minerals Report1 of Sight Sciences, Inc. (“we,” “our,” “us,” “Sight Sciences,” or the “Company”) prepared for calendar year 2024 in accordance with Rule 13p-1 (“Rule 13p-1”) under the Securities Exchange Act of 1934 (the “Act”). Numerous te |
|
| May 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report SIGHT SCIENCES, INC. (Exact name of the registrant as specified in its charter) Delaware 001-40587 80-0625749 (State or other jurisdiction of (Commission (IRS Employer incorporation or organization) File Number) Identification No.) 4040 Campbell Ave, Suite 100 Menlo Park, CA 94025 (Address |
|
| May 8, 2025 |
Sight Sciences Investor Presentation May 2025 Sight Sciences Investor Presentation May 2025 Forward-Looking Statements This presentation, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which statements are subject to considerable risks and uncertainties. |
|
| May 8, 2025 |
FORM 8-K Item 2.02 Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 08, 2025 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 8, 2025 |
Exhibit 99.1 Sight Sciences Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Revenue Guidance MENLO PARK, Calif., May 8, 2025 (GLOBE NEWSWIRE) - Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today reported financial |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40587 SIGHT SCIENCES, INC. |
|
| April 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 23, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 22, 2025 |
Sight Sciences Appoints Gary Burbach to its Board of Directors Exhibit 99.1 Sight Sciences Appoints Gary Burbach to its Board of Directors MENLO PARK, Calif., April 22, 2025 (GLOBE NEWSWIRE) - Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences, or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today that Gerhard (Gary) F. Burbach was ap |
|
| April 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2025 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| March 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40587 SIGHT SCIENCES, |
|
| March 7, 2025 |
Exhibit 10.12 Employment Agreement This Employment Agreement (this “Agreement”), effective as of November 4, 2024 (the “Effective Date”), is made by and between Sight Sciences, Inc., a Delaware corporation (together with any successor thereto, the “Company”), and Brenton Taylor (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”). RECITALS A. It |
|
| March 7, 2025 |
Sight Sciences, Inc. Non-Employee Director Compensation Program Exhibit 10.4 Sight Sciences, Inc. Non-Employee Director Compensation Program Non-employee members of the board of directors (the “Board”) of Sight Sciences, Inc. (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”). The cash and equity compensation described in this Program shall be paid or be made, as applicabl |
|
| March 7, 2025 |
Sight Sciences, Inc. Insider Trading Compliance Policy Exhibit 19.1 Sight Sciences, Inc. Insider Trading Compliance Policy This Insider Trading Compliance Policy (this “Policy”) consists of seven sections: • Section I provides an overview; • Section II sets forth the policies of the Company prohibiting insider trading; • Section III explains insider trading; • Section IV consists of procedures that have been put in place by the Company to prevent insi |
|
| March 7, 2025 |
Exhibit 10.13 Employment Agreement This Employment Agreement (this “Agreement”), effective as of November 4, 2024 (the “Effective Date”), is made by and between Sight Sciences, Inc., a Delaware corporation (together with any successor thereto, the “Company”), and Manohar K. Raheja (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”). RECITALS A. |
|
| March 7, 2025 |
Exhibit 24.1 POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Paul Badawi and Alison Bauerlein, and each of them individually, his and her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him and her and in his and her name, place, and stead, in any and all capac |
|
| March 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 05, 2025 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| March 5, 2025 |
INVESTOR PRESENTATION MARCH 2025 INVESTOR PRESENTATION MARCH 2025 Forward-Looking Statements This presentation, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which statements are subject to considerable risks and uncertainties. |
|
| March 5, 2025 |
Exhibit 99.1 Sight Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Initiates Full Year 2025 Financial Guidance MENLO PARK, Calif., March 5, 2025 (GLOBE NEWSWIRE) - Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard |
|
| January 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2025 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| January 14, 2025 |
Exhibit 99.1 Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2024 Financial Highlights MENLO PARK, Calif., January 14, 2025 (GLOBE NEWSWIRE) - Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today |
|
| January 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2025 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| December 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2024 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 14, 2024 |
LIMITED POWER OF ATTORNEY BANK OF AMERICA CORPORATION EX-99 2 bacpoa.htm BANK OF AMERICA CORPORATION LIMITED POWER OF ATTORNEY BANK OF AMERICA CORPORATION, a Delaware corporation (the "Corporation" ), does hereby make, constitute, and appoint each of Marie Andre, Andres Ortiz Custodio, Kamil Dziedzic, Valerie Ezeagbo, Kelvin Kwo k, Frank Lui, James Todd, Ben Tsoi, Michelle Wong, and Monica Yako as an attorney-in-fact for the Corporation acting for th |
|
| November 14, 2024 |
SGHT / Sight Sciences, Inc. / BANK OF AMERICA CORP /DE/ Passive Investment SC 13G/A 1 doc1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 01)* SIGHT SCIENCES, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 82657M105 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule p |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40587 SIGHT SCIENCES, INC. |
|
| November 7, 2024 |
Exhibit 99.3 Sight Sciences Appoints MK Raheja as Executive Vice President, Research and Development and Brenton Taylor as Executive Vice President, Operations New leadership appointments strengthen Sight Sciences’ commitment to advancing innovative eyecare solutions and supporting scalable operations and growth MENLO PARK, Calif., November 7, 2024 (GLOBE NEWSWIRE) - Sight Sciences, Inc. (Nasdaq: |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 01, 2024 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 7, 2024 |
Exhibit 99.1 Sight Sciences Reports Third Quarter 2024 Financial Results and Updates its Full Year 2024 Adjusted Operating Expense Guidance MENLO PARK, Calif., November 7, 2024 (GLOBE NEWSWIRE) - Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the st |
|
| November 7, 2024 |
INVESTOR PRESENTATION NOVEMBER 2024 INVESTOR PRESENTATION NOVEMBER 2024 Forward-Looking Statements This presentation, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which statements are subject to considerable risks and uncertainties. |
|
| October 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2024 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| September 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2024 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40587 SIGHT SCIENCES, INC. |
|
| August 1, 2024 |
Exhibit 99.1 Sight Sciences Reports Second Quarter 2024 Financial Results and Narrows Full Year 2024 Financial Guidance MENLO PARK, Calif., August 1, 2024 (GLOBE NEWSWIRE) - Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today |
|
| August 1, 2024 |
INVESTOR PRESENTATION AUGUST 2024 INVESTOR PRESENTATION AUGUST 2024 Forward-Looking Statements This presentation, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which statements are subject to considerable risks and uncertainties. |
|
| August 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 01, 2024 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| June 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2024 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| June 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report SIGHT SCIENCES, INC. (Exact name of the registrant as specified in its charter) Delaware 001-40587 80-0625749 (State or other jurisdiction of (Commission (IRS Employer incorporation or organization) File Number) Identification No.) 4040 Campbell Ave, Suite 100 Menlo Park, CA 94025 (Address |
|
| June 3, 2024 |
Conflict Minerals Report as required by Item 1.01 and 1.02 of this Form SD. Exhibit 1.01 CONFLICT MINERALS REPORT OF SIGHT SCIENCES, INC. FOR THE REPORTING PERIOD FROM JANUARY 1 TO DECEMBER 31, 2023 I. Introduction This is the Conflict Minerals Report1 of Sight Sciences, Inc. (“we,” “our,” “us,” “Sight Sciences,” or the “Company”) prepared for calendar year 2023 in accordance with Rule 13p-1 (“Rule 13p-1”) under the Securities Exchange Act of 1934 (the “Act”). Numerous te |
|
| May 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2024 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40587 SIGHT SCIENCES, INC. |
|
| May 2, 2024 |
EXHIBIT 99.1 Sight Sciences Reports First Quarter 2024 Financial Results and Reaffirms Full Year 2024 Financial Guidance MENLO PARK, Calif., May 2, 2024 (GLOBE NEWSWIRE) - Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today re |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 02, 2024 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 2, 2024 | ||
| April 29, 2024 |
Exhibit 99.1 Sight Sciences Announces Successful $34 Million Patent Infringement Verdict Against Alcon and its Hydrus Microstent for Microinvasive Glaucoma Surgery MENLO PARK, Calif. – April 29, 2024 - (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevat |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2024 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| April 26, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40587 SIGHT SCIENCES, |
|
| March 13, 2024 |
Subsidiaries of Sight Sciences, Inc. Exhibit 21.1 Subsidiaries of Sight Sciences, Inc. Legal Name of Subsidiary Jurisdiction of Organization Sight Sciences UK, Ltd. United Kingdom Sight Sciences GmbH Germany |
|
| March 13, 2024 |
Sight Sciences, Inc. Policy for Recovery of Erroneously Awarded Compensation Exhibit 97.1 SIGHT SCIENCES, INC. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION Sight Sciences, Inc. (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of October 2, 2023 (the “Effective Date”). Capitalized terms used in this Policy but not otherwise defined herein are defined in Section 11. 1. Persons Subject to Policy T |
|
| March 13, 2024 |
Exhibit 10.14 FIRST AMENDMENT TO MULTI-TENANT SPACE LEASE This First Amendment To Multi-Tenant Space Lease (this "First Amendment"), dated as of December 6, 2023 (the “Reference Date”), is made and entered into by and between Deerfield Campbell LLC, a California limited liability company ("Landlord"), and Sight Sciences, Inc., a Delaware corporation ("Tenant"), with reference to those matters set |
|
| March 13, 2024 |
Exhibit 24.1 POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Paul Badawi and Alison Bauerlein, and each of them individually, his and her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him and her and in his and her name, place, and stead, in any and all capac |
|
| March 13, 2024 |
Exhibit 4.3 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED The following description of the capital stock of Sight Sciences, Inc. (the “Company”, “we”, “us”, and “our”) and certain provisions of our restated certificate of incorporation (the “Charter”) and restated bylaws (the “Bylaws”) is not intended to be a complet |
|
| March 7, 2024 |
Exhibit 99.1 Sight Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Initiates Full Year 2024 Financial Guidance MENLO PARK, Calif., March 7, 2024 (GLOBE NEWSWIRE) - Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care |
|
| March 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 07, 2024 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| March 7, 2024 |
Investor Presentation March 2024 Investor Presentation March 2024 Forward-Looking Statements This presentation, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which statements are subject to considerable risks and uncertainties. |
|
| February 14, 2024 |
SGHT / Sight Sciences, Inc. / KCK LTD. - SC 13G/A Passive Investment SC 13G/A 1 d642727dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Sight Sciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 82657M105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Chec |
|
| February 13, 2024 |
BANK OF AMERICA CORPORATION LIMITED POWER OF ATTORNEY EX-99 2 bacpoa.htm BANK OF AMERICA CORPORATION LIMITED POWER OF ATTORNEY BANK OF AMERICA CORPORATION, a Delaware corporation (the "Corporation"), does hereby make, constitute, and appoint each of Szabina Biro, Hannah Chae, Andres Ortiz Custodio, Kamil Dziedzic, Krishnan Harihanran, Kelvin Kwok, Frank Lui, James Todd, Michelle Wong, and Monica Yako as an attorney-in-fact for the Corporation acting |
|
| February 13, 2024 |
SGHT / Sight Sciences, Inc. / BANK OF AMERICA CORP /DE/ Passive Investment SC 13G 1 doc1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. N/A)* Sight Sciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 82657M105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| February 7, 2024 |
SGHT / Sight Sciences, Inc. / UBS Group AG - 13G- INITIAL Passive Investment SC 13G 1 13GSGHT.txt 13G- INITIAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.) Sight Sciences, Inc. (Name of Issuer) - Common Stock, par value $0.001 per share (Title of Class of Securities) - 82657M105 (CUSIP Number) - Dec 29, 2023 (Date of Event Which Requires Filing of this Statement) - Check the a |
|
| February 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2024 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| January 23, 2024 |
Exhibit 10.1 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT is made and dated as of January 22, 2024 and is entered into by and among SIGHT SCIENCES |
|
| January 23, 2024 |
Exhibit 4.1 THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY STATE SECURITIES LAWS, AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR, SUBJECT TO SECTION 11 HEREOF, AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COUNS |
|
| January 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2024 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| January 23, 2024 |
Exhibit 99.1 Sight Sciences Announces the Closing of up to $65 Million Senior Secured Credit Facility with Hercules Capital Refinancing replaces prior senior credit facility MENLO PARK, Calif. - January 23, 2024 - (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences”), an eyecare technology company focused on developing and commercializing innovative technology intended to trans |
|
| January 10, 2024 |
SGHT / Sight Sciences, Inc. / D1 Capital Partners L.P. - SIGHT SCIENCES, INC. Passive Investment SC 13G/A 1 p24-0016sc13ga.htm SIGHT SCIENCES, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Sight Sciences, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 82657M105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the approp |
|
| December 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2023 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission |
|
| December 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2023 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| December 1, 2023 |
SGHT / Sight Sciences Inc / Encrantz Staffan - SC 13D/A Activist Investment SC 13D/A 1 d621936dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) Sight Sciences, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 82657M105 (CUSIP Number) Staffan Encrantz Allegro Investment Inc. 525 Middlefield Road, Suite 220 Menlo Park, CA 940 |
|
| December 1, 2023 |
EX-99.A 2 d621936dex99a.htm EX-99.A CUSIP No. 82657M105 13D Page 10 of 10 Pages EXHIBIT A Agreement of Joint Filing The undersigned hereby agree that a single Schedule 13D (or any amendment thereto) relating to the Common Stock of Sight Sciences, Inc. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13D. Date: December 1, 202 |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| November 7, 2023 |
Exhibit 99.1 Sight Sciences Reports Third Quarter 2023 Financial Results and Withdraws Guidance for Full Year 2023 MENLO PARK, Calif., November 7, 2023 (GLOBE NEWSWIRE) - Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today |
|
| November 7, 2023 |
Investor Presentation November 2023 Investor Presentation November 2023 Forward-Looking Statements This presentation, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which statements are subject to considerable risks and uncertainties. |
|
| November 7, 2023 |
Exhibit 10.3 Fourth aMENDMENT to AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT (term LOAN) This FOURTH AMENDMENT TO AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT (TERM LOAN) (this “Agreement”) is made as of this 6th day of November, 2023 (“Effective Date”), by and among SIGHT SCIENCES, INC., a Delaware corporation (“Borrower”), MIDCAP FINANCIAL TRUST, as Agent for Lenders (in such capaci |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40587 SIGHT SCIENCES, INC. |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 07, 2023 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 7, 2023 |
Employment Agreement between Sight Sciences, Inc. and Matthew Link, dated September 11, 2023 Exhibit 10.2 Employment Agreement This Employment Agreement (this “Agreement”), effective as of September 11, 2023 (the “Effective Date”), is made by and between Sight Sciences, Inc., a Delaware corporation (together with any successor thereto, the “Company”), and Matthew Link (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”). RECITALS A. It |
|
| October 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2023 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| October 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2023 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| September 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2023 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission |
|
| September 11, 2023 |
EX-99.1 Exhibit 99.1 Sight Sciences Appoints Matt Link as Chief Commercial Officer Former NuVasive President helped scale high-growth medical device company to over $1 billion in revenue MENLO PARK, Calif. - September 11, 2023 - (GLOBE NEWSWIRE) – Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing innova |
|
| September 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2023 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission |
|
| September 11, 2023 |
EX-99.2 Exhibit 99.2 Sight Sciences Provides Revenue Guidance For the Third Quarter of 2023 and Updates Revenue Guidance For Full Year 2023 MENLO PARK, Calif., September 11, 2023 (GLOBE NEWSWIRE) – Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and imp |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40587 SIGHT SCIENCES, INC. |
|
| August 3, 2023 |
Delivering the Power of Sight Investor Presentation August 2023 Delivering the Power of Sight Investor Presentation August 2023 Forward-Looking Statements This presentation, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which statements are subject to considerable risks and uncertainties. |
|
| August 3, 2023 |
Sight Sciences Reports Second Quarter 2023 Financial Results and Reaffirms Guidance for Full Year 2023 MENLO PARK, Calif. |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 03, 2023 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| June 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2023 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| June 9, 2023 |
Regulation FD Disclosure, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2023 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| June 2, 2023 |
Regulation FD Disclosure, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2023 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report SIGHT SCIENCES, INC. (Exact name of the registrant as specified in its charter) Delaware 001-40587 80-0625749 (State or other jurisdiction of (Commission (IRS Employer incorporation or organization) File Number) Identification No.) 4040 Campbell Ave, Suite 100 Menlo Park, CA 94025 (Address |
|
| May 31, 2023 |
Conflict Minerals Report as required by Item 1.01 and 1.02 of this Form SD. Exhibit 1.01 CONFLICT MINERALS REPORT OF SIGHT SCIENCES, INC. FOR THE REPORTING PERIOD FROM JANUARY 1 TO DECEMBER 31, 2022 I. Introduction This is the Conflict Minerals Report of Sight Sciences, Inc. (“we,” “our,” “us,” “Sight Sciences,” or the “Company”) prepared for calendar year 2022 in accordance with Rule 13p-1 (“Rule 13p-1”) under the Securities Exchange Act of 1934 (the “Act”). Numerous ter |
|
| May 22, 2023 |
Sight Sciences, Inc. 4040 Campbell Ave, Suite 100 Menlo Park, CA 94025 May 22, 2023 CORRESP Sight Sciences, Inc. 4040 Campbell Ave, Suite 100 Menlo Park, CA 94025 May 22, 2023 SUBMITTED VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Ms. Jessica Ansart Re: Sight Sciences, Inc. Acceleration Request Registration Statement on Form S-3 File No. 333-270629 Requested Date: May 24, 2023 Requested Time: 5:0 |
|
| May 22, 2023 |
As filed with the Securities and Exchange Commission on May 22, 2023 S-3/A As filed with the Securities and Exchange Commission on May 22, 2023 Registration No. |
|
| May 8, 2023 |
Employment Agreement between Sight Sciences, Inc. and Alison Bauerlein, dated April 3, 2023 Exhibit 10.1 Employment Agreement This Employment Agreement (this “Agreement”), effective as of April 3, 2023 (the “Effective Date”), is made by and between Sight Sciences, Inc., a Delaware corporation (together with any successor thereto, the “Company”), and Alison Bauerlein (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”). RECITALS A. It i |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40587 SIGHT SCIENCES, INC. |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 08, 2023 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 8, 2023 |
Delivering the Power of Sight Investor Presentation May 2023 ® ™ Delivering the Power of Sight Investor Presentation May 2023 ® ™ Forward-Looking Statements This presentation, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which statements are subject to considerable risks and uncertainties. |
|
| May 4, 2023 |
Exhibit 99.1 Sight Sciences Reports First Quarter 2023 Financial Results and Reaffirms Guidance for Full Year 2023 MENLO PARK, Calif., May 4, 2023 (GLOBE NEWSWIRE) - Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today reported financial results |
|
| May 4, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 04, 2023 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| April 26, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 03, 2023 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| April 3, 2023 |
Sight Sciences Appoints Ali Bauerlein as Chief Financial Officer Exhibit 99.1 Sight Sciences Appoints Ali Bauerlein as Chief Financial Officer MENLO PARK, Calif. - April 3, 2023 - (GLOBE NEWSWIRE) - Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announces the appointment of Alison “Ali” Bauerlein as its C |
|
| April 3, 2023 |
Delivering the Power of Sight Investor Presentation April 2023 ™ Delivering the Power of Sight Investor Presentation April 2023 ™ 1 Forward-Looking Statements This press release, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which statements are subject to considerable risks and uncertainties. |
|
| March 20, 2023 |
United States securities and exchange commission logo March 20, 2023 Paul Badawi President and Chief Executive Officer Sight Sciences, Inc. |
|
| March 16, 2023 |
Exhibit 10.15 Third aMENDMENT to AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT (term LOAN) This THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT (TERM LOAN) (this “Agreement”) is made as of this 28th day of December, 2022 (“Effective Date”), by and among SIGHT SCIENCES, INC., a Delaware corporation (“Borrower”), MIDCAP FINANCIAL TRUST, as Agent for Lenders (in such capaci |
|
| March 16, 2023 |
As filed with the Securities and Exchange Commission on March 16, 2023 S-8 As filed with the Securities and Exchange Commission on March 16, 2023 Registration No. |
|
| March 16, 2023 |
Exhibit 4.3 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED The following description of the capital stock of Sight Sciences, Inc. (the “Company”, “we”, “us”, and “our”) and certain provisions of our restated certificate of incorporation (the “Charter”) and restated bylaws (the “Bylaws”) is not intended to be a complet |
|
| March 16, 2023 |
Exhibit 24.1 POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Paul Badawi and Jim Rodberg, and each of them individually, his and her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him and her and in his and her name, place, and stead, in any and all capacities |
|
| March 16, 2023 |
EX-FILING FEES Exhibit 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) Sight Sciences, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stoc |
|
| March 16, 2023 |
Powers of Attorney (incorporated by reference to the signature page hereto). S-3 Table of Contents As filed with the Securities and Exchange Commission on March 16, 2023 Registration No. |
|
| March 16, 2023 |
Exhibit 10.20 FOURTH aMENDMENT to AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT (REVOLVING LOAN) This FOURTH AMENDMENT TO AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT (REVOLVING LOAN) (this “Agreement”) is made as of this 28th day of December, 2022 (“Effective Date”), by and among SIGHT SCIENCES, INC., a Delaware corporation (“Borrower”), MIDCAP FUNDING IV TRUST, as Agent for Lenders (i |
|
| March 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40587 SIGHT SCIENCES, |
|
| March 16, 2023 |
EX-FILING FEES Exhibit 107.1 Calculation of Filing Fee Tables Form S-3 (Form Type) Sight Sciences, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount o |
|
| March 16, 2023 |
EXHIBIT 4.3 SIGHT SCIENCES, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20 Debt Securities TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate 7 Sectio |
|
| March 16, 2023 |
Employment Agreement between Sight Sciences, Inc. and Jeremy Hayden, dated July 7, 2021 Exhibit 10.10 Employment Agreement This Employment Agreement (this “Agreement”), dated as of July 7, 2021, is made by and between Sight Sciences, Inc., a Delaware corporation (together with any successor thereto, the “Company”), and Jeremy Hayden (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”), and will become effective, if at all, upon the |
|
| March 16, 2023 |
Subsidiaries of Sight Sciences, Inc. Exhibit 21.1 Subsidiaries of Sight Sciences, Inc. Legal Name of Subsidiary Jurisdiction of Organization Sight Sciences UK, Ltd. United Kingdom Sight Sciences GmbH Germany |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2023 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| March 13, 2023 |
Exhibit 99.1 Sight Sciences Reports Fourth Quarter and Full Year 2022 Financial Results MENLO PARK, Calif., March 13, 2023 (GLOBE NEWSWIRE) - Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today reported financial results for the fourth quarter a |
|
| February 14, 2023 |
SGHT / Sight Sciences, Inc. / HEP Partners LLC - SC 13G/A Passive Investment SC 13G/A 1 d417146dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Sight Sciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 82657M105 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check |
|
| February 14, 2023 |
SGHT / Sight Sciences, Inc. / Badawi Paul - SC 13G/A Passive Investment SC 13G/A 1 d412718dsc13ga.htm SC 13G/A Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G/A (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Sight Sciences, Inc. (Name of Issuer) Common Stock (Title of Class of Se |
|
| February 13, 2023 |
SGHT / Sight Sciences, Inc. / KCK LTD. - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Sight Sciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 82657M105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| January 9, 2023 |
Sight Sciences Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Financial Results Exhibit 99.1 Sight Sciences Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Financial Results Company Also Announces CFO Transition MENLO PARK, Calif.— January 9, 2023— Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announc |
|
| January 9, 2023 |
Delivering the Power of Sight Investor Presentation January 2023 ™ EX-99.2 3 sght-ex992.htm EX-99.2 Delivering the Power of Sight Investor Presentation January 2023 ™ 1 Forward-Looking Statements This press release, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Ac |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 05, 2023 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40587 SIGHT SCIENCES, INC. |
|
| November 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 10, 2022 |
Exhibit 99.1 Sight Sciences Reports Third Quarter 2022 Financial Results MENLO PARK, Calif., November 10, 2022 (GLOBE NEWSWIRE) - Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients? lives, today reported financial results for the third quarter ended September 30, 2022. Recent Business Highlight |
|
| November 10, 2022 |
Exhibit 10.1 Certain information marked as [****] has been excluded from this exhibit because it is both (i) not material and (ii) is the type that the Registrant treats as private or confidential. AMENDMENT #2 TO SUPPLY AGREEMENT This Amendment #2 to Supply Agreement (?Amendment?) is made effective as of July 19, 2022 (the ?Amendment Effective Date?) and entered into by and between Sight Sciences |
|
| August 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2022 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| August 23, 2022 |
Delivering the Power of Sight Investor Presentation August 2022 ™ Delivering the Power of Sight Investor Presentation August 2022 ? 1 Forward Looking Statements This presentation, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. |
|
| August 23, 2022 |
Exhibit 99.1 Sight Sciences Introduces the SION? Surgical Instrument ? The First Bladeless Device Used in Goniotomy Featuring bladeless technology, SION is designed to facilitate a smooth, gentle goniotomy procedure MENLO PARK, Calif., August 23, 2022 (GLOBE NEWSWIRE) - Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative solutions |
|
| August 11, 2022 |
Exhibit 99.1 Sight Sciences Reports Second Quarter 2022 Financial Results MENLO PARK, Calif., August 11, 2022 (GLOBE NEWSWIRE) - Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients? lives, today reported financial results for the second quarter ended June 30, 2022. Recent Business Highlights ? G |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40587 SIGHT SCIENCES, INC. |
|
| August 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| August 11, 2022 |
Exhibit 10.1 THIRD aMENDMENT to AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT (REVOLVING LOAN) This THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT (REVOLVING LOAN) (this ?Agreement?) is made as of this 10th day of May, 2022 (?Effective Date?), by and among SIGHT SCIENCES, INC., a Delaware corporation (?Borrower?), MIDCAP FUNDING IV TRUST, as Agent for Lenders (in such c |
|
| July 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2022 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| June 10, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2022 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 19, 2022 |
SGHT / Sight Sciences, Inc. / Encrantz Staffan - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) Sight Sciences, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 82657M105 (CUSIP Number) Staffan Encrantz Allegro Investment Inc. 525 Middlefield Road, Suite 220 Menlo Park, CA 94025 (650) 323-8300 (Name, Address and Te |
|
| May 19, 2022 |
CUSIP No. 82657M105 13D Page 11 of 11 Pages EXHIBIT A Agreement of Joint Filing The undersigned hereby agree that a single Schedule 13D (or any amendment thereto) relating to the Common Stock of Sight Sciences, Inc. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13D. Date: May 19, 2022 Allegro Investment Fund, L.P. By: /s/ |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2022 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 10, 2022 |
Exhibit 10.1 SIGHT SCIENCES, INC. 2021 INCENTIVE AWARD PLAN Sub-Plan for UK EMPLOYEES a. Purpose Pursuant to the powers granted by the Administrator in Section 10.5 of the Sight Sciences, Inc. 2021 Incentive Award Plan (as it may be amended or restated from time to time, the ?Plan?), the Administrator has adopted this Sub-Plan (the ?Sub-Plan?). The purpose of the Sub-Plan is to promote the success |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40587 SIGHT SCIENCES, INC. |
|
| May 10, 2022 |
Delivering the Power of Sight Investor Presentation May 2022 ™ Delivering the Power of Sight Investor Presentation May 2022 ? 1 Forward Looking Statements This presentation, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. |
|
| May 10, 2022 |
Exhibit 99.1 Sight Sciences Reports First Quarter 2022 Financial Results MENLO PARK, Calif., May 10, 2022 (GLOBE NEWSWIRE) - Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients? lives, today reported financial results for the quarter ended March 31, 2022. Recent Business Highlights ? Generated f |
|
| April 29, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 18, 2022 |
SGHT / Sight Sciences, Inc. / SHD GP II, LLC Activist Investment SC 13D/A 1 scientifichealth13da.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Sight Sciences, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 82657M105 (CUSIP Number) Andrew Offer Chief Executive Officer SHD Management, LLC 2305 Cedar Springs, Suite #240 Dallas, Texas 752 |
|
| April 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2022 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| March 24, 2022 |
Exhibit 10.15 Certain information marked as [****] has been excluded from this exhibit because it is both (i) not material and (ii) is the type that the Registrant treats as private or confidential. AMENDMENT #1 TO SUPPLY AGREEMENT This Amendment #1 to Supply Agreement (?Amendment?) is made effective as of January 28, 2022 (the ?Amendment Effective Date?) and entered into by and between Sight Scie |
|
| March 24, 2022 |
Exhibit 4.4 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED The following description of the capital stock of Sight Sciences, Inc. (the ?Company?, ?we?, ?us?, and ?our?) and certain provisions of our restated certificate of incorporation (the ?Charter?) and restated bylaws (the ?Bylaws?) is not intended to be a complet |
|
| March 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40587 SIGHT SCIENCES, |
|
| March 24, 2022 |
Exhibit 99.1 Sight Sciences Reports Fourth Quarter and Full Year 2021 Financial Results MENLO PARK, Calif., March 24, 2022 (GLOBE NEWSWIRE) - Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients? lives, today reported financial results for the quarter and year ended December 31, 2021 |
|
| March 24, 2022 |
Delivering the Power of Sight Investor Presentation March 2022 ™ Delivering the Power of Sight Investor Presentation March 2022 ? 1 Forward Looking Statements This presentation, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. |
|
| March 24, 2022 |
Exhibit 10.14 Second aMENDMENT to AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT (term LOAN) This SECOND AMENDMENT TO AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT (TERM LOAN) (this ?Agreement?) is made as of this 15th day of October, 2021 (?Effective Date?), by and among SIGHT SCIENCES, INC., a Delaware corporation (?Borrower?), MIDCAP FINANCIAL TRUST, as Agent for Lenders (in such capac |
|
| March 24, 2022 |
Exhibit 10.13 Second aMENDMENT to AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT (REVOLVING LOAN) This SECOND AMENDMENT TO AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT (REVOLVING LOAN) (this ?Agreement?) is made as of this 15th day of November, 2021 (?Effective Date?), by and among SIGHT SCIENCES, INC., a Delaware corporation (?Borrower?), MIDCAP FUNDING IV TRUST, as Agent for Lenders (i |
|
| March 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2022 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| March 24, 2022 |
Subsidiaries of Sight Sciences, Inc. Exhibit 21.1 Subsidiaries of Sight Sciences, Inc. Legal Name of Subsidiary Jurisdiction of Organization Sight Sciences UK, Ltd. United Kingdom Sight Sciences GmbH Germany |
|
| March 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2022 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| March 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2022 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 14, 2022 |
SGHT / Sight Sciences, Inc. / Selnick Jesse - SC 13G Passive Investment Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to ? 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to ? 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Sight Sciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 82657M105 (CUSIP Number) Decembe |
|
| February 14, 2022 |
SGHT / Sight Sciences, Inc. / HEP Partners LLC - SC 13G Passive Investment SC 13G 1 d274071dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Sight Sciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 82657M105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the ap |
|
| February 14, 2022 |
SGHT / Sight Sciences, Inc. / Badawi Paul - SC 13G Passive Investment Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to ? 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to ? 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Sight Sciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 82657M105 (CUSIP Number) Decembe |
|
| February 14, 2022 |
JOINT FILING AGREEMENT February 14, 2022 Exhibit 99.1 JOINT FILING AGREEMENT February 14, 2022 Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended (the ?Act?), and the rules and regulations thereunder, each party hereto hereby agrees to the joint filing, on behalf of each of them, of any filing required by such party under Section 13 or Section 16 of the Act or any rule or regulation thereunder (including a |
|
| January 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| January 10, 2022 |
Sight Sciences Announces Preliminary Unaudited Fourth Quarter and Full Year 2021 Financial Results Exhibit 99.1 Sight Sciences Announces Preliminary Unaudited Fourth Quarter and Full Year 2021 Financial Results MENLO PARK, Calif., January 10, 2022 (GLOBE NEWSWIRE) ? Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients? lives, today announced preliminary unaudited financial results |
|
| December 10, 2021 |
Delivering the Power of Sight Investor Presentation December 2021 ? Exhibit 99.1 1 Forward Looking Statements This presentation, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amende |
|
| December 10, 2021 |
SGHT / Sight Sciences, Inc. / Encrantz Staffan - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) Sight Sciences, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 82657M105 (CUSIP Number) Staffan Encrantz Allegro Investment Inc. 525 Middlefield Road, Suite 220 Menlo Park, CA 94025 (650) 323-8300 (Name, Address and Tel |
|
| December 10, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2021 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 10, 2021 |
Execution Version Exhibit 10.1 FIRST aMENDMENT TO AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT (REVOLVING LOAN) This FIRST AMENDMENT TO AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT (REVOLVING LOAN) (this ?Agreement?) is made as of this 5th day of October, 2021 (?Effective Date?), by and among SIGHT SCIENCES, INC., a Delaware corporation (?Borrower?), MIDCAP FUNDING IV TRUST, as Agent f |
|
| November 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40587 SIGHT SCIENCES, INC. |
|
| November 10, 2021 |
Sight Sciences Reports Third Quarter 2021 Financial Results MENLO PARK, Calif., November 10, 2021 (GLOBE NEWSWIRE) - Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients? lives, today reported financial results for the quarter ended September 30, 2021. Recent Business Highlights ? Ge |
|
| November 10, 2021 |
Execution Version Exhibit 10.2 FIRST aMENDMENT TO AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT (term LOAN) This FIRST AMENDMENT TO AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT (TERM LOAN) (this ?Agreement?) is made as of this 5th day of October, 2021 (?Effective Date?), by and among SIGHT SCIENCES, INC., a Delaware corporation (?Borrower?), MIDCAP FINANCIAL TRUST, as Agent for Lenders |
|
| September 9, 2021 |
Delivering the Power of Sight Investor Presentation September 2021 ™ Delivering the Power of Sight Investor Presentation September 2021 ? 1 Forward Looking Statements This presentation, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. |
|
| September 9, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 09, 2021 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 12, 2021 |
Sight Sciences Reports Second Quarter 2021 Financial Results Exhibit 99.1 Sight Sciences Reports Second Quarter 2021 Financial Results MENLO PARK, Calif., August 12, 2021 (GLOBE NEWSWIRE) - Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients? lives, today reported financial results for the quarter ended June 30, 2021. Recent Business Highligh |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40587 SIGHT SCIENCES, INC. |
|
| August 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2021 Sight Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40587 80-0625749 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| August 10, 2021 |
SGHT / Sight Sciences, Inc. / D1 Capital Partners L.P. - SIGHT SCIENCES, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Sight Sciences, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 82657M105 (CUSIP Number) July 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sch |
|
| July 27, 2021 |
SGHT / Sight Sciences, Inc. / SHD GP II, LLC - SCHEDULE 13D Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Sight Sciences, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 82657M105 (CUSIP Number) Andrew Offer Chief Executive Officer SHD Management, LLC 2305 Cedar Springs, Suite #240 Dallas, Texas 75201 (214) 303-1540 (Name, Address and Te |
|
| July 19, 2021 |
Restated Certificate of Incorporation of Sight Sciences, Inc. Exhibit 3.1 RESTATED CERTIFICATE OF INCORPORATION OF SIGHT SCIENCES, INC. The name of the corporation is Sight Sciences, Inc. The corporation was originally incorporated by the filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware on February 10, 2010. This Restated Certificate of Incorporation of the corporation, which restates and integrates and |
|
| July 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 19, 2021 Sight Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40587 80-0625749 (State or other jurisdiction of incorporation or organization) |
|
| July 19, 2021 |
Amended and Restated Bylaws of Sight Sciences, Inc. Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF SIGHT SCIENCES, INC. (a Delaware corporation) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING 2 2.5 ADVANCE NOTICE PROCEDURES FOR N |
|
| July 16, 2021 |
As filed with the Securities and Exchange Commission on July 15, 2021 As filed with the Securities and Exchange Commission on July 15, 2021 Registration No. |
|
| July 16, 2021 |
Exhibit 4.3 RESTATED CERTIFICATE OF INCORPORATION OF SIGHT SCIENCES, INC. The name of the corporation is Sight Sciences, Inc. The corporation was originally incorporated by the filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware on February 10, 2010. This Restated Certificate of Incorporation of the corporation, which restates and integrates and |
|
| July 15, 2021 |
10,000,000 Shares Common Stock Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-257320 PROSPECTUS 10,000,000 Shares Common Stock This is Sight Sciences, Inc.?s initial public offering. We are offering 10,000,000 shares of our common stock. Prior to this offering, there has been no public market for our common stock. The initial public offering price of our common stock is $24 per share. Our common stock h |
|
| July 14, 2021 | ||
| July 14, 2021 |
As filed with the Securities and Exchange Commission on July 14, 2021 S-1/A Table of Contents As filed with the Securities and Exchange Commission on July 14, 2021 Registration No. |
|
| July 12, 2021 |
July 12, 2021 Via EDGAR Transmission Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| July 12, 2021 |
Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 BofA Securities Inc. One Bryant Park New York, New York 10036 Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 Piper Sandler & Co. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 July 12, 2021 Securities and Exchange Commission Division of Corporation Finance Office of Manufacturing 100 F |
|
| July 8, 2021 |
Form of Restated Certificate of Incorporation of the Registrant Exhibit 3.3 RESTATED CERTIFICATE OF INCORPORATION OF SIGHT SCIENCES, INC. The name of the corporation is Sight Sciences, Inc. The corporation was originally incorporated by the filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware on February 10, 2010. This Restated Certificate of Incorporation of the corporation, which restates and integrates and |
|
| July 8, 2021 |
2021 Incentive Award Plan and form of option agreements thereunder Exhibit 10.2 SIGHT SCIENCES, INC. 2021 INCENTIVE AWARD PLAN ARTICLE I. PURPOSE The Plan?s purpose is to enhance the Company?s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities. Capitalized terms used in the Plan are defined in Article XI. ARTICLE II. ELIGIBILIT |
|
| July 8, 2021 |
Employment Agreement between Sight Sciences, Inc. and David Badawi, M.D., dated July 7, 2021 Exhibit 10.14 Employment Agreement This Employment Agreement (this ?Agreement?), dated as of July 7, 2021, is made by and between Sight Sciences, Inc., a Delaware corporation (together with any successor thereto, the ?Company?), and David Badawi, M.D. (?Executive?) (collectively referred to herein as the ?Parties? or individually referred to as a ?Party?), and will become effective, if at all, upo |
|
| July 8, 2021 |
Employment Agreement between Sight Sciences, Inc. and Shawn O'Neil, date July 7, 2021 Exhibit 10.12 Employment Agreement This Employment Agreement (this ?Agreement?), dated as of July 7, 2021, is made by and between Sight Sciences, Inc., a Delaware corporation (together with any successor thereto, the ?Company?), and Shawn O?Neil (?Executive?) (collectively referred to herein as the ?Parties? or individually referred to as a ?Party?), and will become effective, if at all, upon the |
|
| July 8, 2021 |
Specimen Stock Certificate evidencing the shares of common stock Exhibit 4.2 COMMON STOCK SHARES CUSIP 82657M 10 5 SEE REVERSE FOR CERTAIN DEFINITIONS INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE THIS CERTIFIES THAT IS THE RECORD HOLDER OF FULLY PAID AND NON-ASSESSABLE SHARES OF COMMON STOCK, $.001 PAR VALUE PER SHARE, OF SIGHT SCIENCES, INC. transferable on the books of the Corporation in person or by duly authorized attorney upon surrender of this cer |
|
| July 8, 2021 |
Sight Sciences, Inc. 2021 Employee Stock Purchase Plan Exhibit 10.4 SIGHT SCIENCES, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN ARTICLE I. PURPOSE The purpose of this Plan is to assist Eligible Employees of the Company and its Designated Subsidiaries in acquiring a stock ownership interest in the Company. The Plan consists of two components: (i) the Section 423 Component and (ii) the Non-Section 423 Component. The Section 423 Component is intended to quali |
